14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 09, 2026
ACHV vs ADIL: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
ACHV Overall Winner
6-Pillar Tally: ACHV 5 – 0 ADIL (1 Tie)
Matrix Metrics: ACHV 6 – 0 ADIL
As of Nov 09, 2026, Achieve Life Sciences, Inc. (ACHV) is the stronger overall head-to-head candidate over Adial Pharmaceuticals, Inc (ADIL) in the Tradestie Institutional Equity Comparison Engine, winning 6–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ACHV carries a Unified Composite Score of 56.6/100 (HOLD) at $6.78 (35.3x Forward P/E, 0.0% operating margin), whereas ADIL carries 32.8/100 (SELL) at $5.05 (N/M Forward P/E, 0.0% operating margin).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ACHV vs ADIL. Trailing 12-month operating profitability (ACHV 0.0% vs ADIL 0.0%) and valuation multiples (ACHV 35.3x vs ADIL N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $692.8M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
ADIL Moat ProfileCyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $9.7M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ ACHV vs ADIL Key Questions & Quantitative Answers
As of Nov 09, 2026, Achieve Life Sciences, Inc. (ACHV) is the stronger overall head-to-head candidate over Adial Pharmaceuticals, Inc (ADIL) in the Tradestie Institutional Equity Comparison Engine, winning 6–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ACHV carries a Unified Composite Score of 56.6/100 (HOLD) at $6.78 (35.3x Forward P/E, 0.0% operating margin), whereas ADIL carries 32.8/100 (SELL) at $5.05 (N/M Forward P/E, 0.0% operating margin). Technically, ACHV sits in a Neutral phase (RSI 48.1, BREAKOUT options structure) and ADIL sits in a Markup phase (RSI 62.9, UNCLASSIFIED options structure).
ACHV leads the Growth & Scale pillar: ACHV posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ADIL at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ACHV generates N/A in USD-normalized revenue versus N/A for ADIL. In operating R&D and SG&A reinvestment, ACHV deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ADIL.
ACHV screens cheaper on headline valuation multiples. ACHV trades at 35.3x Forward P/E, 35.3x Trailing P/E, 17.68x PEG, and N/M EV/Revenue (unreported FCF margin), whereas ADIL trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ACHV (-845.0% ROE) versus ADIL (-2011.6% ROE) capital efficiency.
In options market volatility and institutional positioning, ACHV carries 88.3% implied volatility (23rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKOUT options structure phase (1.73β · 62% Vol realized risk). By comparison, ADIL carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.63β · 153% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 09, 2026. For educational research only; not investment advice.